Insider Trading Alert - CAVM, MAT And HTA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 6, 2014, 125 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $50.00 to $263,000,081.93.

Highlighted Stocks Traded by Insiders:

Cavium (CAVM) - FREE Research Report

Pangrazio Vincent P, who is SVP,Gen. Counsel & Secretary at Cavium, sold 3,325 shares at $42.90 on May 6, 2014. Following this transaction, the SVP,Gen. Counsel & Secretary owned 11,036 shares meaning that the stake was reduced by 23.15% with the 3,325-share transaction.

The shares most recently traded at $41.63, down $1.27, or 3.05% since the insider transaction. Historical insider transactions for Cavium go as follows:

  • 4-Week # shares sold: 3,750
  • 12-Week # shares sold: 105,250
  • 24-Week # shares sold: 205,250

The average volume for Cavium has been 815,900 shares per day over the past 30 days. Cavium has a market cap of $2.3 billion and is part of the technology sector and electronics industry. Shares are up 20.92% year-to-date as of the close of trading on Tuesday.

Cavium, Inc. designs, develops, and markets semiconductor processors for intelligent and secure networks. The company operates through Semiconductor Products, and Software and Services segments. The company has a P/E ratio of 1087.5. Currently, there are 10 analysts who rate Cavium a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CAVM - FREE

TheStreet Quant Ratings rates Cavium as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the stock itself is trading at a premium valuation. Get the full Cavium Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Mattel (MAT) - FREE Research Report

Walker Geoffrey H, who is EVP Global Brands Fisher-Price at Mattel, sold 2,449 shares at $39.42 on May 6, 2014. Following this transaction, the EVP Global Brands Fisher-Price owned 21,054 shares meaning that the stake was reduced by 10.42% with the 2,449-share transaction.

The shares most recently traded at $39.31, down $0.11, or 0.29% since the insider transaction. Historical insider transactions for Mattel go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 14,258
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 14,258
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 19,258

The average volume for Mattel has been 4.1 million shares per day over the past 30 days. Mattel has a market cap of $13.3 billion and is part of the consumer goods sector and consumer durables industry. Shares are down 17.68% year-to-date as of the close of trading on Tuesday.

Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl. It also publishes Advice and Activity books and the American Girl magazine. The stock currently has a dividend yield of 3.86%. The company has a P/E ratio of 15.9. Currently, there are no analysts who rate Mattel a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MAT - FREE

TheStreet Quant Ratings rates Mattel as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Mattel Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Healthcare Trust of America (HTA) - FREE Research Report

Dewald Maurice J, who is Director at Healthcare Trust of America, bought 3,000 shares at $11.87 on May 6, 2014. Following this transaction, the Director owned 70,000 shares meaning that the stake was reduced by 4.48% with the 3,000-share transaction.

The shares most recently traded at $12.15, up $0.28, or 2.3% since the insider transaction. Historical insider transactions for Healthcare Trust of America go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 100,000
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 100,000
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 100,000

The average volume for Healthcare Trust of America has been 1.8 million shares per day over the past 30 days. Healthcare Trust of America has a market cap of $2.8 billion and is part of the financial sector and real estate industry. Shares are up 21.24% year-to-date as of the close of trading on Tuesday.

Healthcare Trust of America is a fully integrated, self-administered and internally managed real estate investment trust, or REIT. The company acquires, owns and operates medical office buildings and other facilities that serve the healthcare industry. The stock currently has a dividend yield of 4.85%. The company has a P/E ratio of 107.8. Currently, there are 3 analysts who rate Healthcare Trust of America a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HTA - FREE

TheStreet Quant Ratings rates Healthcare Trust of America as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins. Get the full Healthcare Trust of America Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists